CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing ...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...
The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...
The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator ...
A rare cause of hereditary cognitive decline known as CSF1R-Related Disorder (CSF1R-RD) gets its name from mutations in the ...
Miplyffa treats Niemann-Pick disease type C, which progressively impacts the abilities to speak, swallow, and walk or move ...
Children's Hospital of Michigan is treating the first person in Michigan with a newly approved gene-editing therapy for beta thalassemia.
Fifty years after it was first coined, the diagnosis of fetal alcohol spectrum disorder (FASD) now does more harm than good ...
Sep. 12, 2024 — A new study by more than 50 climate scientists worldwide provides the clearest projection that Antarctica's ice sheet will retreat rapidly after 2100 under current carbon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback